Healius May Not Get the Strong 4Q It Needs -- Market Talk

Dow Jones04-04

2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's Ebit is likely to total around A$67 million in FY 2024, below guidance of A$70 million-A$80 million. "We continue to note a subdued environment for Australian Healthcare Services, with an ongoing low GP bulk-billing rate," he says. Despite the likely earnings miss, Healius's base pathology Ebit margin is likely to have expanded in 2H by some 490 basis points versus 1H, says Jefferies, which rates the stock at underperform. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

April 03, 2024 17:40 ET (21:40 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424806543?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-04 05:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424806543","market":"sh","top_or_hot":-1,"title":"Healius May Not Get the Strong 4Q It Needs -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's Ebit is likely to total around A$67 million in FY 2024, below guidance of A$70 million-A$80 million. \"We continue to note a subdued environment for Australian Healthcare Services, with an ongoing low GP bulk-billing rate,\" he says. Despite the likely earnings miss, Healius's base pathology Ebit margin is likely to have expanded in 2H by some 490 basis points versus 1H, says Jefferies, which rates the stock at underperform. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2024 17:40 ET (21:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healius May Not Get the Strong 4Q It Needs -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealius May Not Get the Strong 4Q It Needs -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-04 05:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7509","symbol_name":"中概股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2424806543","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424806543","pubTimestamp":1712180400,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's Ebit is likely to total around A$67 million in FY 2024, below guidance of A$70 million-A$80 million. \"We continue to note a subdued environment for Australian Healthcare Services, with an ongoing low GP bulk-billing rate,\" he says. Despite the likely earnings miss, Healius's base pathology Ebit margin is likely to have expanded in 2H by some 490 basis points versus 1H, says Jefferies, which rates the stock at underperform. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7509":"中概股","HLS.AU":"HEALIUS LTD","BK7124":"保健护理服务","BK7501":"新冠治疗股"},"translate_title":"Healius可能得不到它所需要的强劲的4Q——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLS.AU":0.9},"content_text":"2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's Ebit is likely to total around A$67 million in FY 2024, below guidance of A$70 million-A$80 million. \"We continue to note a subdued environment for Australian Healthcare Services, with an ongoing low GP bulk-billing rate,\" he says. Despite the likely earnings miss, Healius's base pathology Ebit margin is likely to have expanded in 2H by some 490 basis points versus 1H, says Jefferies, which rates the stock at underperform. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2024 17:40 ET (21:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424806543"}